HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results

Stock News04-01

HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9, with a turnover of HK$62.17 million. On March 31, HAIXI PHARMA announced its full-year performance, posting revenue of approximately RMB582 million, a year-on-year increase of 24.79%. Net profit reached about RMB177 million, up 30.09% compared to the previous year, with earnings per share at RMB2.55. The company attributed the revenue growth to enhanced marketing efforts during the year, which boosted sales of its products Haihuitong® and Anbili®. Notably, Haihuitong® was newly included in the National Volume-Based Procurement (VBP) program specification (5mg/20mg×14 tablets) in 2025, effectively driving expansion in hospital channels and boosting sales in the end market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108606328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108606328","market":"nz","top_or_hot":-1,"title":"HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results","media":"Stock News","content":"<p>HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9, with a turnover of HK$62.17 million. On March 31, HAIXI PHARMA announced its full-year performance, posting revenue of approximately RMB582 million, a year-on-year increase of 24.79%. Net profit reached about RMB177 million, up 30.09% compared to the previous year, with earnings per share at RMB2.55. The company attributed the revenue growth to enhanced marketing efforts during the year, which boosted sales of its products Haihuitong® and Anbili®. Notably, Haihuitong® was newly included in the National Volume-Based Procurement (VBP) program specification (5mg/20mg×14 tablets) in 2025, effectively driving expansion in hospital channels and boosting sales in the end market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-01 10:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9, with a turnover of HK$62.17 million. On March 31, HAIXI PHARMA announced its full-year performance, posting revenue of approximately RMB582 million, a year-on-year increase of 24.79%. Net profit reached about RMB177 million, up 30.09% compared to the previous year, with earnings per share at RMB2.55. The company attributed the revenue growth to enhanced marketing efforts during the year, which boosted sales of its products Haihuitong® and Anbili®. Notably, Haihuitong® was newly included in the National Volume-Based Procurement (VBP) program specification (5mg/20mg×14 tablets) in 2025, effectively driving expansion in hospital channels and boosting sales in the end market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1108606328","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108606328","pubTimestamp":1775010018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","02637":"海西新药","VXUS":"国际股票ETF-Vanguard","BK1191":"制药"},"translate_title":"2025财年业绩强劲，海西药业股价飙升逾8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1,"VXUS":1},"content_text":"HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9, with a turnover of HK$62.17 million. On March 31, HAIXI PHARMA announced its full-year performance, posting revenue of approximately RMB582 million, a year-on-year increase of 24.79%. Net profit reached about RMB177 million, up 30.09% compared to the previous year, with earnings per share at RMB2.55. The company attributed the revenue growth to enhanced marketing efforts during the year, which boosted sales of its products Haihuitong® and Anbili®. Notably, Haihuitong® was newly included in the National Volume-Based Procurement (VBP) program specification (5mg/20mg×14 tablets) in 2025, effectively driving expansion in hospital channels and boosting sales in the end market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108606328","isCrawlerRequest":true}